Evidence map›Paper›PMID 42151259›Full record

ArticleScientific reports2026

Comparative analysis and correlation of cancer hotspot proteins and cell markers in tumor-normal adjacent breast and kidney samples using RPPA and LC-MS.

Krisztina Paal, Noemi Karnok, Csaba Konrad, David Bui, Fanni Bugyi, Lilla Turiák, Christos Chinopoulos

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Krisztina Paal *Department of Biochemistry, Semmelweis University, Budapest, 1094, Hungary.
Noemi Karnok *Department of Biochemistry, Semmelweis University, Budapest, 1094, Hungary.
Csaba KonradFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, 10065, USA.
David BuiDepartment of Biochemistry, Semmelweis University, Budapest, 1094, Hungary.
Fanni BugyiMTA-TTK Lendület (Momentum) Glycan Biomarker Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, 1117, Hungary.
Lilla TuriákMTA-TTK Lendület (Momentum) Glycan Biomarker Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, 1117, Hungary.
Christos ChinopoulosDepartment of Biochemistry, Semmelweis University, Budapest, 1094, Hungary. chinopoulos.christos@semmelweis.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer proteomics is crucial for understanding tumor biology, yet consistent quantification of clinically relevant proteins across analytical platforms remains challenging. Here, we compared Reverse Phase Protein Array (RPPA) and Liquid Chromatography-Mass Spectrometry (LC-MS) using identical lysate aliquots prepared from matched tumor and adjacent normal tissues from breast and kidney cancer patients. We focused on proteins encoded by genes represented in the Ion AmpliSeq Cancer Hotspot Panel v2 and included representative cellular markers. RPPA was applied to the larger sample set, whereas data-dependent, data-independent, and targeted parallel reaction monitoring LC-MS modes were performed on a smaller subset of lysates. RPPA identified tumor-normal differences for several proteins and cell markers, while LC-MS quantified a smaller overlapping subset in the matched samples analyzed by both platforms. Cross-platform comparison showed that agreement was partial and strongly protein dependent: some targets displayed concordant tumor/normal fold changes, whereas others exhibited weak or even opposite-direction changes. Targeted PRM modestly improved agreement for selected discordant proteins, but substantial discrepancies remained. These data indicate that RPPA and LC-MS are not interchangeable for quantifying all targets in this panel, calling for a rather confirmatory approach: concordant findings increase confidence in selected candidate biomarkers, whereas discordant findings identify targets that require cautious interpretation.

Indexed as

Biomarkers, TumorBreastBreast NeoplasmsKidneyKidney NeoplasmsLiquid Chromatography-Mass SpectrometryNeoplasm ProteinsProtein Array AnalysisProteomicsChromatography, LiquidFemaleHumansBiomarkers, TumorNeoplasm ProteinsLiquid chromatography-mass spectrometryOncogeneProteomicsReverse phase protein arrayTumor-suppressor gene

Identifiers

PMID42151259
PMCPMC13377106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.